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Immunotoxicity of perfluorinated alkylates:
calculation of benchmark doses based on serum
concentrations in children
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Abstract
Background: Immune suppression may be a critical effect associated with exposure to perfluorinated compounds
(PFCs), as indicated by recent data on vaccine antibody responses in children. Therefore, this information may be
crucial when deciding on exposure limits.
Methods: Results obtained from follow-up of a Faroese birth cohort were used. Serum-PFC concentrations were
measured at age 5 years, and serum antibody concentrations against tetanus and diphtheria toxoids were obtained
at age 7 years. Benchmark dose results were calculated in terms of serum concentrations for 431 children with
complete data using linear and logarithmic curves, and sensitivity analyses were included to explore the impact of
the low-dose curve shape.
Results: Under different linear assumptions regarding dose-dependence of the effects, benchmark dose levels were
about 1.3 ng/mL serum for perfluorooctane sulfonic acid and 0.3 ng/mL serum for perfluorooctanoic acid at a
benchmark response of 5%. These results are below average serum concentrations reported in recent population
studies. Even lower results were obtained using logarithmic dose–response curves. Assumption of no effect below the
lowest observed dose resulted in higher benchmark dose results, as did a benchmark response of 10%.
Conclusions: The benchmark dose results obtained are in accordance with recent data on toxicity in experimental
models. When the results are converted to approximate exposure limits for drinking water, current limits appear to be
several hundred fold too high. Current drinking water limits therefore need to be reconsidered.
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Background
Perfluorinated compounds (PFCs) have been in use for
over 60 years in a wide array of applications. PFCs were
first manufactured in the US from about 1947, with
perfluorooctanoic acid (PFOA) and perfluorooctane sul-
fonic acid (PFOS) as primary products [1]. PFC was later
found to contaminate ground and surface water, and
PFOS was found to accumulate in freshwater fish [2].
These compounds possess a strong carbon-fluorine bond,
which leads to persistence of the PFCs in the environment
and the human body [2]. Thus, the high thermal, chemical
and biological inertness that make the PFCs useful for
many industrial purposes at the same time also generates
an environmental hazard.
Serum-PFC analyses conducted by the Centers for Dis-
ease Control and Prevention (CDC) show that PFOS and
PFOA are detectable in virtually all Americans [3], with
children often showing higher serum concentrations than
adults [4]. Analyses of paired samples of maternal serum
and cord serum show that PFCs are transferred through
the human placenta [5,6]. Due to global dissemination of
PFCs, their serum concentrations in children and preg-
nant women even in the remote locations, such as the
Faroe Islands [7], are similar to US levels. Exposures to
some PFCs in the Faroes may occur primarily through
marine diets [8]. Despite the extensive use of these com-
pounds for many decades, and the persistence and
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cumulative properties of the PFCs, the toxicology data
base is still incomplete and has allowed only preliminary
risk assessments so far.
Using animal toxicity data, calculations of benchmark
dose levels (BMDLs) have been carried out for a 10% devi-
ation relative to control values (i.e., a Benchmark Response
or BMR of 10%); they resulted in serum concentrations of
23 mg/L and 35 mg/L for PFOA and PFOS, respectively
[9-11]. Toxicokinetic modeling and standard assumptions
about water intake then allow derivation of acceptable
drinking water levels [11,12]. So far, the U.S. Environmen-
tal Protection Agency (EPA) has issued a draft risk assess-
ment of PFOA in 2005, but no final version has yet been
published, nor has a Reference Dose (RfD) been defined.
However, the EPA has issued provisional health advisories
of 0.4 μg/L (400 ng/L) for PFOA and 0.2 μg/L (200 ng/L)
for PFOS in drinking water [13]. Similarly, the Agency for
Toxic Substances and Disease Registry concluded in its
draft toxicological profile in 2009 that there was insuffi-
cient evidence at the time to develop a minimal risk level
[1]. For chronic exposure, state authorities have issued
limits for PFC concentrations in drinking the water, e.g., in
Minnesota [14], where the limit for both PFOS and PFOA
is 0.3 μg/L (300 ng/L). The limits were based on PFOS ef-
fects on the liver and thyroid, and PFOA effects on the
liver, fetal development, reduction in red blood cell num-
bers, and immune system changes in experimental studies
[11]. A lower guidance limit of 0.04 μg/L (40 ng/L) has
been determined for PFOA by the state of New Jersey [15].
Other agencies, such as the European Food Safety Author-
ity [16] have recommended similar exposure limits that re-
lied on the same toxicology data while using different
default assumptions.
PFC toxicity in animal models at first suggested the liver
as a main target organ, but so far chronic toxicity data
only in the rat have been published [1,12,17,18]. However,
recent evidence suggests that toxicology outcomes used in
derivation of exposure limits may not represent the most
sensitive endpoints. Thus, interference with mammary
gland development in mice with developmental exposure
seems to occur at low exposures; benchmark dose calcula-
tions using a variety of models showed that a 10% BMR
corresponded to a serum-based BMDL for PFOA of 23–
25 μg/L (or ng/mL) [12,17]. This BMDL differs by a factor
of 1,000 from the previously mentioned BMDL based on
liver toxicity (i.e., 23 mg/L or 23,000 μg/L). Thus, current
limits for PFOA in drinking water based on the latter
value may not be as protective as intended, despite the use
of uncertainty factors.
Likewise, immunotoxicity of PFCs has been demon-
strated in rodent models, avian models, reptilian models,
and mammalian and nonmammalian wildlife [19]. For ex-
ample, in a commonly used mouse model, PFOA effects
include decreased spleen and thymus weights, decreased
thymocyte and splenocyte counts, decreased immuno-
globulin response, and changes in specific populations of
lymphocytes in the spleen and thymus. Reduced survival
after influenza infection has also been reported as an ap-
parent effect of PFOS exposure in mice [20]. Another study
found that the lowest observed effect level (LOEL) for
males corresponded to an average serum-PFOS concentra-
tion of 92 ng/g (about 94 μg/L), though 7-fold higher in fe-
males [21]. The LOEL serum concentration in males is
similar to typical levels found in serum samples from sub-
jects exposed to contaminated drinking water [22].
Given the concern about immunotoxicity as a possible
critical effect [19] and the possibility of developmental
toxicity [23], studies in child populations have recently fo-
cused on antibody responses to childhood immunizations
as a clinically relevant parameter that reflects major im-
mune system functions [24]. The subjects have all received
the same doses of vaccine antigens at the same ages and
can then be examined at similar ages, i.e., similar intervals
after the most recent vaccination [25]. Our studies focused
on the fishing community of the Faroe Islands [8], and
these prospective population data [7] seem appropriate for
calculating benchmark doses as a contribution to future
risk assessments.
While benchmark dose calculations from toxicology
data are fairly straightforward, using epidemiological stud-
ies can be more complicated due to the need for covariate
adjustments [26]. In addition, decisions on dose–response
models may be crucial, as a null exposure group is usually
not available, thus requiring extrapolations beyond the ex-
posure interval observed.
Methods
A birth cohort in the Faroe Islands was recruited and
consisted of 656 consecutive singleton births from late
1997 to early 2000. Prospective follow-up included 587 co-
hort members participated in one or both examinations at
ages 5 and 7 years [7], of whom 460 participated on both
examinations, and complete data with serum analyses were
obtained for 431. As exposure indicator, we used the PFC
concentrations in the child’s serum obtained at the clinical
examination at age 5 years. The outcomes were the specific
antibody concentrations against tetanus and diphtheria tox-
oids in serum at age 7 years. Of the PFCs, PFOS and PFOA
showed the highest concentrations (Table 1), similar to
levels reported from the US [3]. We also measured mater-
nal pregnancy serum PFC concentrations, which showed
strong negative correlations with antibody concentrations
at age 5 years. However, we chose to focus on the PFCs in
the child’s serum at age 5 and their uniformly negative asso-
ciations with antibody levels at age 7, as these data appar-
ently represented the greatest sensitivity to PFC exposure
so far documented and were not confounded by exposures
to other environmental chemicals. The dependence of the
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antibody concentrations on PFC exposures was determined
by generalized additive models [27]. Written maternal con-
sent was obtained, and the protocol was approved by the
ethical review committee at the Faroe Islands and by the re-
view board at the US institution.
Benchmark calculations
The data were analyzed as continuous variables in SAS
version 9.2. Although a clinical cut-off level exists for
antibody concentrations that represent long-term pro-
tection, this limit is somewhat arbitrary, and transform-
ation of the continuous data to a dichotomous variable
results in a loss of information.
Benchmark calculations were therefore based on regres-
sion models with antibody concentrations as dependent
variables while PFC-concentrations were included as in-
dependent variables along with potential confounders sex,
age and booster type at age 5 [7]. To achieve normally
distributed residuals, antibody concentrations were log-
transformed. Thus, we based models on the formula
log antibodyð Þ ¼ α0 þ α1  sexþ α2  ageþ α3
 booster typeþ f dð Þ þ ε;
where d is the PFC concentration (PFOS or PFOA) mea-
sured at 5 years and f is the dose–response function satis-
fying f(0) = 0. We modeled the PFC-effect using a
linear-dose response function [f(d) = β × d], a logarithmic
model [f(d) = β × log(d + 1)] and the so-called K-power
model [f(d) = β × dK, K > =1]. As the dose–response rela-
tionship at low doses may differ from the one at higher
doses, we also used a piecewise linear model, which
allowed for a difference in slopes at the median exposure.
Calculations were carried out for PFOS and PFOA separ-
ately. Given their close correlations, it was not possible to
include mutual adjustment in the models.
The BMD is the dose which reduces the outcome by a
certain percentage (BMR) compared to unexposed controls
[28,29]. Several different BMR values have been used in the
past, and lower BMR levels are known to result in de-
creased BMD results, in part because the uncertainty in-
creases [26]. By convention, a 10% BMR is often used for
experimental toxicology data [28,29]. On the other hand, a
decreased antibody response to vaccinations must be
regarded as an important adverse effect, thus supporting
the selection of a lower BMR. Thus, in human studies, a
BMR of 5% is often chosen [29]. We therefore calculated
BMD results for BMR values of 5% and 10%. An advantage
of a log-transformed response is that BMD can be esti-
mated independently of the confounders as the dose where
the dose–response function is equal to log(1-BMR), i.e., the
BMD, will satisfy the equation f(BMD) = log(1-BMR).
As the main result of the calculations, the benchmark
dose level (BMDL) is defined as the lower one-sided 95%-
confidence limit of the BMD. In the dose–response
models with linear parameters (linear, log and piecewise
linear models), the derivation of closed form expressions
for the BMDL is straight forward [30]. Based on the esti-
mated uncertainty in the parameter estimates, the lower
confidence limit of the dose-effect function [f(d)] can be
determined. The BMDL is given as the dose where this
confidence limit is equal to log(1-BMR). For non-linear
models, the BMDL was calculated using the (iterative)
profile likelihood method. The fit of the models was based
on minus two times the log-maximum likelihood function
(−2 log(L)), where a smaller value indicates a better fit.
The low dose fit was measured by calculating -2log(L)
based on children with exposures in the lowest quartile.
As a consequence of the relatively steep dose–response
relationships, the BMDs were sometimes lower than the
minimum observed exposure, and some results therefore
depended on a part of the dose–response curve, for which
the data does not hold any information. As a sensitivity
analysis, we therefore developed a low-dose threshold ver-
sion of each of the dose–response models used. Each of
these models was identical to the original dose–response
model within the observed dose range, but with a flat
dose–response slope below the lowest dose observed
(Figure 1).
Results
Descriptive results are shown in Table 1. Children who
participated in one clinical examination, but not the
other, did not seem to differ in terms of exposure levels
and antibody concentrations from those cohort subjects
who participated in both examinations.
Generally, the log model yielded lower BMDs, but only
for the PFOS did these results provide a (marginally) better
fit than the linear slope (Table 2). The model-dependence
was similar for tetanus and diphtheria antibody concentra-
tions as outcome variables. When using the linear slope
and a BMR of 5%, the BMDL was about 1.3 ng/mL and
Table 1 Characteristics of 431 Faroese birth cohort
members with complete data from examinations at ages
5 and 7 years
Variable Result
Girl, n (%) 223 (48.5)
Birth weight, mean (SD) g 3724 (505)
Birth weight≤ 2500 g, n (%) 3 (0.7)
Age at 5-year examnination, mean (SD) years 5.0 (0.1)
Age at 7-year examination, mean (SD) years 7.5 (0.1)
Serum-PFOS concentration at age 5, ng/mLa 17.3 (14.1; 21.3)
Serum-PFOA concentration at age 5, ng/mLa 4.06 (3.33; 4.95)
Anti-tetanus concentration at age 7, IU/mLa 1.80 (0.75; 4.60)
Anti-diphtheria concentration at age 7, IU/mLa 0.80 (0.40; 1.60)
a Median (interquartile range).
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0.3 ng/mL for PFOS and PFOA, respectively. The piece-
wise linear curve showed BMDL results about half the
level of the linear dose–response curve, while the logarith-
mic curve showed even lower results. In the K-power
model, the power parameter was estimated to one, and
this model was therefore identical to the linear model. As
expected, results were higher at a BMR of 10%.
All dose–response models had normally distributed re-
siduals with a homogeneous scatter. The piecewise linear
generally had the closest fit, but it was not significantly
better than the alternative models. For the association be-
tween PFOS and the diphtheria antibody concentration,
Figure 1 illustrates the agreement between the different
models within the observed data range. The linear func-
tion is less steep at the low doses, which explains why this
model yields higher benchmark results.
Using the low-dose threshold models with a flat dose–
response below the lowest observed exposure levels, the
BMDL results for the linear curve were about 5-fold
higher than for the non-threshold curve (Table 3). The
low-dose threshold results for both the piecewise and the
logarithmic curves approximated those obtained using a
linear slope.
Discussion
The present report presents the first benchmark dose re-
sults for human PFC exposure. It relies on serum-PFC
measurements at age 5, and serum concentrations of spe-
cific antibodies two years later as clinically relevant mea-
sures of immune functions. The size and homogeneity of
the study population and the high participation rate are
major strengths [7]. The associations that appeared the
strongest were selected for BMD calculations. Although
this selection was not based on an a priori hypothesis and
therefore could result in bias, structural equation model
analyses suggest that the overall effects of PFCs on anti-
bodies were stronger than most individual effects [7]. Con-
comitant exposure to PCBs did not cause any important
confounding. We included age and sex as covariates, but
they affected the results to a negligible degree only.
However, a weakness is the close correlation between
PFOA and PFOS, which makes mutual PFC adjustment
difficult. Structural equation models suggest that the
joint effects of major PFCs were stronger than those that
could be ascribed to single compounds [7], and it is
therefore possible that each of the major PFCs contribute
to the effects. Given the strong experimental support for
immunotoxicity of both PFOA and PFOS [19], the BMD
levels would seem to provide approximate levels of con-
cern for human exposures.
The choice of dose–response models is known to result
in different BMD results from epidemiological studies,
where unexposed controls are often missing [26]. In the
absence of prior knowledge regarding the shape of the
curve, we used two common curve shapes (linear and
logarithmic) to explore the dependence of the data on
these two assumptions. The two curves fit the data equally
well, and no statistical justification is therefore available
for choosing one set of results above the others. The linear
curve is often used as a default, and we therefore further
examined a model with a piecewise linear shape and one
with a flat slope below the lowest observed level of expos-
ure. For each of the two PFCs, these sensitivity analyses
showed that the BMDL results remained low. As antici-
pated, the 5% BMR results in BMDL values somewhat
below those for 10%, but differences between the curve
shapes were not smaller at an increased BMR.
The vaccine-specific antibody concentrations used in
our recent study [7] are thought to represent sensitive
immunotoxicity parameters. Other clinical outcome mea-
sures may be less sensitive. For example, hospitalization of
363 children up to an average age of 8 years for infectious
diseases (such as middle ear infection, pneumonia, and ap-
pendicitis) was not associated with PFOS and PFOA
Figure 1 Estimated dose–response functions for the
relationship between PFOS and the diphtheria-antibody
concentration. Curve A is estimated as a generalized additive model.
Curve B is the log-function, C is piecewise linear, and D is linear. The
low-dose threshold models (see Table 3) assume a flat curve below the
lowest observed dose indicated by the dotted vertical line, i.e., that a
threshold exists at the lowest serum-PFOS concentration observed. The
bars on the horizontal scale indicate the serum-PFOS concentration of
each participating cohort member.
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concentrations in serum from pregnant women from the
Danish National Birth Cohort [31]. Multiple social, demo-
graphic and other factors may have affected these results,
and hospitalization does not seem to be a sensitive or ap-
propriate test of the presence of immune system dysfunc-
tion. In adults exposed to PFOA through contaminated
drinking water, the serum-PFOA concentration was asso-
ciated with lower serum concentrations of total IgA, IgE
(in females only), though not IgG [32]. Although confirm-
ation from other human studies is therefore lacking so far,
experimental studies offer support that specific immuno-
globulin concentrations may be sensitive indicators of im-
mune system dysfunctions [19].
Interaction with peroxisome proliferator-activated re-
ceptors (PPARs) may be involved in the immunotoxic
mechanisms [1,19]. While human PPARα expression is
significantly less than that of rodents, current evidence
suggests that both PPARα-dependent and -independent
pathways may be relevant to PFC immunotoxicity [33].
In human white blood cells in vitro, mechanistic studies
of PFC-induced suppression of cytokine secretion dem-
onstrated that PPARα activation was involved in the
PFOA-induced immunotoxicity, while other pathways
appeared responsible in regard to the effects of PFOS
[34]. White blood cells from human volunteers showed ef-
fects at PFOS concentrations in the medium of 0.1 μg/mL
(100 ng/mL), which was the lowest concentration tested
[35]. This level is similar to concentrations seen both in af-
fected male mice [21] and in subjects exposed to contami-
nated drinking water [22].
Based on both experimental and human studies, an
approximate BMDL of 1 μg/L would seem to be an ap-
propriate order of magnitude for calculation of exposure
limits for the PFCs. As the BMDL assumes equal sensi-
tivity within the population studied, current guidelines
[28,29] require that the BMDL be divided by an uncer-
tainty factor of 10 to take into account the existence of
subjects with increased vulnerability. A concentration of
about 0.1 ng/mL could then be used as the serum-based
RfD for the PFCs (somewhat higher for PFOS and lower
for PFOA).
Using mammary gland development as a sensitive out-
come in experimental studies [17], a BMDL of about
23 ng/mL serum was calculated for PFOA [12]. Taking
into account interspecies differences in vulnerability and
using a total uncertainty factor of 30, an RfD of 0.8 ng/mL
serum would be derived from this BMDL. Thus, although
referring to a different endpoint, this calculation is in good
accordance with the one estimated from our epidemio-
logical data.
A serum-based RfD less than 1 ng/mL for PFOS and
PFOA would be below most concentrations reported in
Table 2 Benchmark results for postnatal PFC exposure (in terms of serum concentrations in ng/mL measured at
5 years) with vaccine antibody concentrations at 7 years as the outcomes
BMR = 5% BMR = 10% Fit (−2log(L))
Outcome Exposure Model* BMD BMDL BMD BMDL Full scale Low dose
Tetanus PFOS Linear 2.70 1.31 5.55 2.69 1719.81 313.78
Log 0.13 0.07 0.29 0.14 1719.30 313.75
Piecewise 1.45 0.56 2.98 1.16 1719.54 313.54
PFOA Linear 0.38 0.25 0.77 0.51 1712.43 391.53
Log 0.07 0.04 0.14 0.09 1712.88 391.63
Piecewise 0.52 0.16 1.07 0.34 1712.33 391.64
Diphtheria PFOS Linear 2.30 1.25 4.72 2.57 1656.86 314.00
Log 0.11 0.06 0.24 0.13 1655.96 313.38
Piecewise 0.98 0.49 2.01 1.01 1655.77 313.10
PFOA Linear 0.59 0.33 1.21 0.68 1656.15 362.37
Log 0.10 0.06 0.22 0.12 1656.14 362.39
Piecewise 0.48 0.17 0.99 0.34 1656.12 362.30
*K-power model was identical to the linear model.
Table 3 Results of sensitivity analyses using low-dose
threshold models with no effect below the lowest
observed exposures
BMR = 5% BMR = 10%
Outcome/Exposure Model BMD BMDL BMD BMDL
Diphtheria/PFOS Linear 8.48 7.43 10.90 8.75
Log 6.96 6.62 7.89 7.11
Piecewise 7.16 6.67 8.19 7.19
Tetanus/PFOA Linear 1.70 1.57 2.10 1.83
Log 1.48 1.43 1.65 1.53
Piecewise 1.85 1.49 2.40 1.66
Benchmark results for serum concentrations (in ng/mL) measured at 5 years in
regard to vaccine antibody concentrations at 7 years. Results are given for the
exposures and outcomes showing the lowest results in Table 1.
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recent studies [3,7,31]. Importantly, estimated RfD values
below 1 ng/mL are at least 100-fold below those used for
calculation of current water contamination limits. PFOA
concentrations in drinking water are known to correlate
with the serum concentrations of long-term residents in
Ohio and West Virginia at an approximate ratio of about
1:100 [12,15,36]. Thus, from these data, a serum-based
RfD of 0.1 ng/mL can be translated to a water concentra-
tion of 1 ng/L, or 0.001 μg/L (assuming that no other
sources contributed to the PFOA exposure). The current
EPA limit for this PFC is 300-fold higher. Thus, the recent
evidence on PFC immunotoxicity in humans and toxicity
in animal models suggests that current limits for drinking
water contamination are too permissive and must be de-
creased substantially.
Conclusions
BMDL results were about 1.3 ng/mL serum for PFOS and
0.3 ng/mL serum for PFOA at a benchmark response of
5%. Lower values were obtained with the logarithmic curve,
and higher results with a larger benchmark response. The
BMDL results are in accordance with recent data on tox-
icity in experimental models. When converted to approxi-
mate exposure limits for drinking water, current limits
appear to be several hundred fold too high. Current drink-
ing water limits therefore need to be reconsidered in the
light of the observed immunotoxicity associated with PFC
exposure.
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